Similar articles

Abstract: Objective: Many investigations have studied the associations between matrix metalloproteinase-9 (MMP-9) C1562T polymorphisms and coronary artery disease (CAD). However, the conclusions of these studies were inconsistent. Therefore, this study was aimed at clarifying the association between MMP-9 C1562T polymorphisms and CAD in a large-scale meta-analysis. Methods: The PubMed and Embase databases were retrieved to collect all publications on the association between MMP-9 C1562T polymorphisms and CAD. Then the odd ratios (ORs) and 95% confidence intervals (95% CIs) for C1562T TT+TC versus CC genotype between CAD and the control groups were evaluated. Subgroup analysis was also performed according to different races. The meta-analysis was performed by Stata 10.0. Results: Sixteen case-control studies were included in our meta-analysis, involving 11 032 CAD patients and 4628 non-CAD controls. Compared with C allele carriers, East Asian T allele carriers TT+TC had a significantly higher risk of CAD (OR=1.43; 95% CI: 1.03–1.99; P=0.031); however, there were no significant associations in Western populations (OR=1.06; 95% CI: 0.96–1.18; P=0.240) or West Asians (OR=1.13; 95% CI: 0.75–1.70; P=0.565). When further analyzing the association between C1562T polymorphisms and myocardial infarction (MI, the most serious type of CAD), the risk of TT+TC genotype versus CC genotype for MI was significantly higher for the overall (OR=1.21; 95% CI: 1.04–1.40; P=0.012) and for East Asians (OR=1.58; 95% CI: 1.26–1.97; P=0.000) but not in Western populations (OR=1.12; 95% CI: 0.99–1.26; P=0.078). Conclusions: Our meta-analysis suggested an obvious ethnic difference in the association between MMP-9 C1562T polymorphisms and CAD. MMP-9 C1562T polymorphism was significantly related to CAD in East Asians. However, no significant associations were observed in either West Asians or Western populations.

基质金属蛋白酶-9 C1562T基因多态性与冠心病关系的meta分析

研究目的：探讨基质金属蛋白酶-9（MMP-9）C1562T基因多态性与冠心病之间的关系。
创新要点：通过综合分析，明确了MMP-9 C1562T基因多态性与冠心病的发生存在种族差异性，解决了以往单个研究由于样本量偏少而得出不同结论的弊端。
研究方法：利用meta分析可以扩大样本量的优势，分析了MMP-9 C1562T基因多态性与冠心病间的关系，且研究结论更为可靠。
重要结论：MMP-9 C1562T基因多态性与冠心病的发生存在显著的种族差异性：在东亚人群中，MMP-9 C1562T基因多态性与冠心病的发生密切相关；在西方人群及西亚人群中，MMP-9 C1562T基因多态性与冠心病的发生无显著相关性。

关键词：冠心病；基质金属蛋白酶-9；基因多态性；Meta分析

[1] Alp, E., Menevse, S., Tulmac, M., 2009. Lack of association between matrix metalloproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol, 28(7):343-350. 

[2] Asselbergs, F.W., Reynolds, W.F., Cohen-Tervaert, J.W., 2004. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med, 116(6):429-430. 

[3] Blankenberg, S., Rupprecht, H.J., Poirier, O., 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 107(12):1579-1585. 

[4] Brown, D.L., Hibbs, M.S., Kearney, M., 1995. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation, 91(8):2125-2131. 

[5] Cho, H.J., Chae, I.H., Park, K.W., 2002. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J Hum Genet, 47(2):88-91. 

[6] Demacq, C., de Souza, A.P., Machado, A.A., 2006. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta, 365(1-2):183-187. 

[7] Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., 2008. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med, 46(1):57-63. 

[8] Fallah, S., Seifi, M., Ghasemi, A., 2010. Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J Clin Lab Anal, 24(5):305-310. 

[9] Galis, Z.S., Sukhova, G.K., Lark, M.W., 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest, 94(6):2493-2503. 

[10] Ghaderian, S.M., Akbarzadeh Najar, R., Tabatabaei Panah, A.S., 2010. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis, 21(6):330-335. 

[11] Haberbosch, W., Gardemann, A., 2005. Gelatinase B C_(−1562)T polymorphism in relation to ischaemic heart disease. Scand J Clin Lab Invest, 65(6):513-522. 

[12] Horne, B.D., Camp, N.J., Carlquist, J.F., 2007. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J, 154(4):751-758. 

[13] Izidoro-Toledo, T.C., Guimaraes, D.A., Belo, V.A., 2011. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol, 383(6):547-554. 

[14] Jefferis, B.J., Whincup, P., Welsh, P., 2010. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis, 208(2):557-563. 

[15] Johnson, C., Galis, Z.S., 2004. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol, 24(1):54-60. 

[16] Kai, H., Ikeda, H., Yasukawa, H., 1998. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol, 32(2):368-372. 

[17] Kim, J.S., Park, H.Y., Kwon, J.H., 2002. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J, 43(4):473-481. 

[18] Koh, Y.S., Chang, K., Kim, P.J., 2008. A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int J Cardiol, 127(3):430-432. 

[19] Lacchini, R., Metzger, I.F., Luizon, M., 2010. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol, 29(11):649-655. 

[20] Loftus, I.M., Naylor, A.R., Goodall, S., 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke, 31(1):40-47. 

[21] Lopez, A.D., Mathers, C.D., Ezzati, M., 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367(9524):1747-1757. 

[22] Marenberg, M.E., Risch, N., Berkman, L.F., 1994. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med, 330(15):1041-1046. 

[23] Metzger, I.F., Luizon, M.R., Lacchini, R., 2012. Genetic variants in matrix metalloproteinase-9 gene modify metalloproteinase-9 levels in black subjects. DNA Cell Biol, 31(4):504-510. 

[24] Morgan, A.R., Zhang, B., Tapper, W., 2003. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med (Berl), 81(5):321-326. 

[25] Nanni, S., Melandri, G., Hanemaaijer, R., 2007. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res, 149(3):137-144. 

[26] Newby, A.C., 2005. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev, 85(1):1-31. 

[27] Nuzzo, D., Vasto, S., Balistreri, C.R., 2006. Role of proinflammatory alleles in longevity and atherosclerosis: results of studies performed on −1562C/T MMP-9 in centenarians and myocardial infarction patients from sicily. Ann N Y Acad Sci, 1089(1):496-501. 

[28] Opstad, T.B., Pettersen, A.A., Weiss, T.W., 2012. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta, 413(1-2):113-120. 

[29] Pasterkamp, G., Schoneveld, A.H., Hijnen, D.J., 2000. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis, 150(2):245-253. 

[30] Pollanen, P.J., Karhunen, P.J., Mikkelsson, J., 2001. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol, 21(9):1446-1450. 

[31] Souza-Costa, D.C., Sandrim, V.C., Lopes, L.F., 2007. Anti-inflammatory effects of atorvastatin: modulation by the T–786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis, 193(2):438-444. 

[32] Tayebjee, M.H., Lip, G.Y., Tan, K.T., 2005. Plasma matrix metalloproteinase-9, tissue inhibitor of metallo-proteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol, 96(3):339-345. 

[33] Wang, J., Warzecha, D., Wilcken, D., 2001. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond), 101(1):87-92. 

[34] Wang, L., Ma, Y.T., Xie, X., 2012. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost, 18(1):72-78. 

[35] Welsh, P., Whincup, P.H., Papacosta, O., 2008. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM, 101(10):785-791. 

[36] Zhang, B., Ye, S., Herrmann, S.M., 1999. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99(14):1788-1794. 

[37] Zhang, B., Henney, A., Eriksson, P., 1999. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet, 105(5):418-423. 

[38] Zhi, H., Wang, H., Ren, L., 2010. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol Biol Rep, 37(1):13-20.